IRD
NASDAQ · Biotechnology
Opus Genetics Inc
$4.80
-0.17 (-3.42%)
Open$4.89
Previous Close$4.97
Day High$4.94
Day Low$4.73
52W High$5.81
52W Low$0.90
Volume—
Avg Volume991.3K
Market Cap404.54M
P/E Ratio—
EPS$-0.81
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+383.5% upside
Current
$4.80
$4.80
Target
$23.21
$23.21
$16.63
$23.21 avg
$31.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 19.23M | 27.13M | 29.63M |
| Net Income | -67,169,803 | -85,276,939 | -1,185,756 |
| Profit Margin | -349.3% | -331.9% | -4.0% |
| EBITDA | -65,113,412 | -87,258,769 | -1,569,658 |
| Free Cash Flow | — | — | -1,455,645 |
| Rev Growth | -29.1% | -29.1% | +20.7% |
| Debt/Equity | 0.07 | 0.07 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |